The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.
April 27th 2024
KDpredict uses age, sex, eGFR, and albuminuria to calculate 1-5 year risk of kidney failure and death in chronic kidney disease, outperforming the kidney failure risk equation.
Navigating Newer Approaches to Managing IgA Nephropathy
April 14, 2024
Register Now!
New York GU™ 17th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
View More
Expert Illustrations and Commentaries™: Emerging Therapies and Treatment Strategies to Improve Care for Your Patients with Anemia in CKD
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Community Practice Connections: 7th Annual School of Nursing Oncology™
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Bridging the Care Gap in Anemia in CKD: A Comprehensive Guide to Enhancing Patient Care
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do the Experts Select and Sequence Therapies to Optimize Patient Outcomes and Quality of Life in Advanced Prostate Cancer?
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
GU Tumor Board®: Real World Strategies to Inform Individualized Care in Renal Cell Carcinoma
View More
Medical Crossfire®: Optimizing Care for Patients With Anemia and Chronic Kidney Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Chronic Kidney Disease: Sleep Problems Increases with Disease Progression
April 13th 2015Lack of sleep and chronic kidney disease (CKD) independently lead to hypertension, diabetes mellitus, lower quality of life, and shorter life expectancy. Severity of CKD and sleep disturbances may also worsen diabetes and hypertension synergistically.
The US Food and Drug Administration (FDA) issued a strong warning on a drug used to treat iron deficiency anemia in patients with chronic kidney disease. Intravenous injections of ferumoxytol (Feraheme/Amag Pharmaceuticals) can cause serious allergic reactions including death in patients who are sensitive to the drug, the FDA cautioned in a new boxed warning. The drug was approved in 2009.
Kidney Disease Risk Higher with Longer Exposure to Antiretrovirals, Study Finds
March 1st 2015Chronic kidney disease developed in association with exposure to antiretrovirals in people with initially normal levels of estimated glomerular filtration rate (eGFR) was not limited to increased incidence immediately after starting therapy but in fact increased over time and exposure.
Approval for Hemodialysis Drug
The US Food and Drug Administration approved ferric pyrophosphate citrate (Triferic/Rockwell) for use as an iron replacement therapy in patients with end-stage renal disease, the company announced. It is also indicated for chronic kidney disease. The drug is for adults.
More Intensive Blood Pressure Goals Reserved for Most Severe Kidney Disease: KDIGO
November 17th 2014Recent updates by the 8th Joint National Committee (JNC 8), the American and International Societies of Hypertension (ASH-ISH), and KDIGO recommend target blood pressure of less than 140/90 mm Hg for most individuals, including those with CKD.
Updated Blood Pressure Guidelines from Major Bodies Agree on Targets in Kidney Disease
November 17th 2014Two major sets of hypertension guidelines released in 2014 contain more common threads than differences, and are intended to serve different purposes. Clinicians seeking guidance for managing hypertension in chronic kidney disease (CKD) can look for this common ground to avoid "guideline overload."
Hypertension Guidelines Still Leave Room for Clinical Judgment
November 17th 2014Guidelines for hypertension have converged on a blood pressure target of less than 140/90 mm Hg for most individuals with chronic kidney disease (CKD). However, studies still need to clarify optimal BPs for advanced disease and optimal cardiovascular prevention.
Pharmacogenetics Helps Fine-Tune Warfarin Dosing in Kidney Disease
November 16th 2014Though warfarin has long been the mainstay of anticoagulation in atrial fibrillation (AF), dosing is complicated by a host of factors, and the drug has a famously narrow therapeutic range. One way to fine-tune warfarin therapy is to account for genetic variation.
Consider Individual Risks, Benefits for Anticoagulation in Chronic Kidney Disease
November 15th 2014Anticoagulation is recommended for members of the general population with atrial fibrillation, but its significant risks must be weighed carefully in the medically fragile chronic kidney disease population.
Atrial Fibrillation Associated with Accelerated Renal Disease; Ablation May Help
November 15th 2014Treatment of atrial fibrillation (AF) in patients with CKD may help prevent disease progression. Ablation has been shown produce marked improvement in kidney function as measured by eGFR. A prospective study of individuals undergoing catheter ablation for AF showed that most patients remained AF-free, and that eGFR improved significantly for those with persistent or longstanding persistent AF.
Cinacalcet May Reduce Cardiovascular Risk for Older Kidney Disease Patients: EVOLVE Re-Analysis
November 14th 2014Secondary hyperparathyroidism can occur in CKD when the kidney loses its ability to produce active metabolites of vitamin D, and reduces phosphorus excretion. Cinacalcet seeks to interrupt the progression to severe unremitting hyperparathyroidism by mimicking calcium to the calcium-sensing receptors that control parathyroid hormone levels.
Diabetic Kidney Disease: New Consensus Document
October 22nd 2014Prompted by almost-epidemic rates of diabetes in the United States and globally, the American Diabetes Association recently convened a consensus panel to examine diabetic kidney disease, one of the most frequent complications associated with diabetes.
Metformin Inappropriately Prescribed to Older Diabetics with Chronic Kidney Disease
July 28th 2014Clinicians must anticipate changes in kidney function during acute illness and surgical procedures, as well as frequently reassess metformin use in older patients, since kidney function declines predictably with age.
Bioengineered Blood Vessel Offers Potential Improvements for Dialysis Patients
November 21st 2013Initial results from human clinical trials involving the use of bioengineered blood vessels could point the way to cost-effective alternative therapies for hemodialysis patients with end-stage renal disease.
Vascular Calcification Shown on X-Ray Assesses Cardiovascular Risks in Chronic Kidney Disease
November 8th 2013A recent study presented at Kidney Week 2013 suggests that a plain X-ray is a reliable and inexpensive tool for assessing the risks of cardiovascular events and death in patients who have chronic kidney disease (CKD) and are not on dialysis.